偽性腸閉塞治療の世界市場レポート 2025年

偽性腸閉塞治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で309億米ドルに成長します。予測期間の成長は、研究開発と医薬品開発、遠隔医療と遠隔モニタリング、患者教育とサポート、償還政策に起因すると考えられます。予測期間の主な動向には、高度な消化管運動検査、免疫調節療法、栄養介入、データ分析、aiなどがあります。

パーキンソン病の有病率の増加は、当面の偽性腸閉塞（IPO）治療市場拡大の大きな要因になると予測されます。パーキンソン病は、主に脳の黒質領域にあるドーパミン産生ニューロンに影響を及ぼす神経変性疾患です。パーキンソン病患者におけるIPOの罹患率の増加は、腸神経系への影響に起因しており、消化管運動障害を引き起こし、巨大結腸症や急性結腸性仮性閉塞のような状態を引き起こす可能性があります。例えば、米国を拠点とする非営利団体パーキンソン病財団によると、2022年12月時点でパーキンソン病の診断数は顕著に増加しており、米国では年間約9万人が診断されており、これは以前の推定値から50%も大幅に増加しています。さらに、2030年までに世界のパーキンソン病患者数は120万人に達すると予測されています。したがって、パーキンソン病患者数の増加は、偽性腸閉塞治療市場の成長を牽引する要因となっています。

がん患者数の増加は、今後数年間における偽性腸閉塞（IPO）治療市場の成長を牽引すると予想されます。がんは、体内の特定の細胞が制御不能に増殖し、他の部位に転移する疾患です。座りがちな生活習慣、食生活の乱れ、タバコの使用などの要因は、がんのリスクを高める。がんに関連する偽性腸閉塞（IPO）の治療では、基礎にあるがんを管理することが重要なアプローチとなり、偽閉塞に伴う消化器症状を緩和または解決することができます。例えば、2022年10月、英国を拠点とする非営利団体マクミラン・キャンサー・サポートは、英国では現在約300万人ががんと共に生活しており、この数は2025年までに350万人、2030年までに400万人、2040年までに530万人に増加するという予測を報告しています。このように、がん罹患率の増加が偽性腸閉塞（IPO）治療市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の偽性腸閉塞治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の偽性腸閉塞治療市場：成長率分析
• 世界の偽性腸閉塞治療市場の実績：規模と成長, 2019-2024
• 世界の偽性腸閉塞治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の偽性腸閉塞治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の偽性腸閉塞治療市場：条件付き、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 世界の偽性腸閉塞治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤
• 手術
• 食生活
• その他の治療
• 世界の偽性腸閉塞治療市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• バイオスパイ
• 血液検査
• 胃内容排出検査
• 画像検査
• その他の診断
• 世界の偽性腸閉塞治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と臨床
• 外来診療センター
• その他のエンドユーザー
• 世界の偽性腸閉塞治療市場、タイプ別サブセグメンテーション：抗生物質、実績と予測, 2019-2024, 2024-2029F, 2034F
• 広域抗生物質
• 狭域スペクトル抗生物質
• 世界の偽性腸閉塞治療市場、タイプ別サブセグメンテーション：抗うつ薬、実績と予測, 2019-2024, 2024-2029F, 2034F
• 三環系抗うつ薬（TCA）
• 選択的セロトニン再取り込み阻害薬（SSRI）
• 世界の偽性腸閉塞治療市場、タイプ別サブセグメンテーション：下痢止め薬、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロペラミド
• サリチル酸ビスマス

第7章 地域別・国別分析

• 世界の偽性腸閉塞治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の偽性腸閉塞治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 偽性腸閉塞治療市場：競合情勢
• 偽性腸閉塞治療市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck Sharp & Dohme Corp Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Takeda Pharmaceutical Company Limited
• Amgen PLC
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Mylan N.V.
• Biogen Inc.
• Penn Medicine
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Allergan plc
• Torrent Pharmaceuticals Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 偽性腸閉塞治療市場2029：新たな機会を提供する国
• 偽性腸閉塞治療市場2029：新たな機会を提供するセグメント
• 偽性腸閉塞治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intestinal pseudo-obstruction (IPO) treatment addresses a rare gastrointestinal motility disorder exhibiting symptoms akin to a mechanical bowel obstruction, even in the absence of a physical blockage. The goals of treating intestinal pseudo-obstruction involve symptom relief, enhancement of intestinal motility, complication management, and overall improvement in quality of life.

The primary drug classes encompassed in IPO treatment comprise antibiotics, antidepressants, and antidiarrheals. Antibiotics represent a potent category of medications employed for combating bacterial infections in both human and animal patients. Diverse treatment modalities, such as medication, surgery, dietary adjustments, decompression, and others, are administered via various routes, including oral, intravenous, among others. Multiple diagnostic approaches, including physical examinations, biopsies, blood tests, gastric emptying tests, imaging studies, among others, are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

The intestinal pseudo-obstruction market research report is one of a series of new reports from The Business Research Company that provides intestinal pseudo-obstruction market statistics, including intestinal pseudo-obstruction industry global market size, regional shares, competitors with a intestinal pseudo-obstruction market share, detailed intestinal pseudo-obstruction market segments, market trends and opportunities and any further data you may need to thrive in the intestinal pseudo-obstruction industry. This intestinal pseudo-obstruction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $23.46 billion in 2024 to $24.87 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $30.9 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

The increasing prevalence of Parkinson's disease is anticipated to be a significant driver for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Parkinson's disease is a neurodegenerative condition primarily affecting dopamine-producing neurons in the substantia nigra region of the brain. The heightened incidence of IPO in individuals with Parkinson's disease is attributed to its impact on the enteric nervous system, leading to gastrointestinal dysmotility, potentially resulting in conditions like megacolon or acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a U.S.-based non-profit organization, there has been a notable increase in Parkinson's disease diagnoses, with approximately 90,000 Americans being identified annually, representing a substantial 50% surge from previous estimates. Moreover, it is projected that by 2030, the global population with Parkinson's disease will reach 1.2 million. Consequently, the escalating cases of Parkinson's disease serve as a driving force for the growth of the intestinal pseudo-obstruction treatment market.

The rising number of cancer cases is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the coming years. Cancer is a disease where certain cells in the body grow uncontrollably and spread to other areas. Factors such as sedentary lifestyles, poor eating habits, and tobacco use increase the risk of cancer. In the treatment of intestinal pseudo-obstruction (IPO) related to cancer, managing the underlying cancer is a key approach, which can help alleviate or resolve the gastrointestinal symptoms associated with pseudo-obstruction. For example, in October 2022, Macmillan Cancer Support, a UK-based non-profit organization, reported that around 3 million people in the UK are currently living with cancer, with projections suggesting this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the growing incidence of cancer is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

The increasing demand for personalized medicine is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the future. Personalized medicine leverages genetic information to tailor treatments to individual patients. The growing demand for this approach is driven by advancements in genomics, biotechnology, and the rising awareness of genetic testing and precision healthcare. Personalized medicine offers customized treatments for intestinal pseudo-obstruction, taking into account a patient's unique genetic makeup and lifestyle, which enhances symptom management and the effectiveness of therapy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the growing demand for personalized medicine is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic move is poised to bolster Ironwood's innovation capabilities and expand its portfolio, ultimately reshaping the benchmark for care in the field of gastrointestinal (GI) medicine. The acquisition will also propel advancements in the treatment of GI disorders, with VectivBio Holding AG, a clinical-stage biotechnology company based in Switzerland, specializing in the treatment of severe and rare gastrointestinal conditions, including Intestinal Pseudo-Obstruction (IPO).

Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2024. The regions covered in intestinal pseudo-obstruction (IPO) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intestinal pseudo-obstruction (IPO) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intestinal Pseudo-Obstruction Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestinal pseudo-obstruction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intestinal pseudo-obstruction treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intestinal pseudo-obstruction treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antibiotics; Antidepressants; Antidiarrheals
• 2) By Treatment: Medication; Surgery; Diet; Decompression; Other Treatments
• 3) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
• 4) By Diagnosis: Physical Examination; Biopsy; Blood Test; Gastric Emptying Tests; Imaging Tests; Other Diagnosis
• 5) By End User: Clinic; Hospitals; Other End Users
• Subsegments:
• 1) By Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
• 2) By Antidepressants: Tricyclic Antidepressants (TCAs); Selective Serotonin Reuptake Inhibitors (SSRIs)
• 3) By Antidiarrheals: Loperamide; Bismuth Subsalicylate
• Companies Mentioned: F. Hoffmann-La Roche AG; Merck Sharp & Dohme Corp; Bayer AG; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intestinal Pseudo-Obstruction Treatment Market Characteristics

3. Intestinal Pseudo-Obstruction Treatment Market Trends And Strategies

4. Intestinal Pseudo-Obstruction Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Intestinal Pseudo-Obstruction Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intestinal Pseudo-Obstruction Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intestinal Pseudo-Obstruction Treatment Market Growth Rate Analysis
• 5.4. Global Intestinal Pseudo-Obstruction Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intestinal Pseudo-Obstruction Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intestinal Pseudo-Obstruction Treatment Total Addressable Market (TAM)

6. Intestinal Pseudo-Obstruction Treatment Market Segmentation

• 6.1. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• 6.2. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Diet
• Other Treatmrnt
• 6.3. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Examination
• Biospy
• Blood Test
• Gastic Emptying Tests
• Imaging Tests
• Other Diagnosis
• 6.4. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinicals
• Ambulatory Care Centers
• Other End-Users
• 6.5. Global Intestinal Pseudo-Obstruction Treatment Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
• 6.6. Global Intestinal Pseudo-Obstruction Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tricyclic Antidepressants (TCAs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• 6.7. Global Intestinal Pseudo-Obstruction Treatment Market, Sub-Segmentation Of Antidiarrheals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Loperamide
• Bismuth Subsalicylate

7. Intestinal Pseudo-Obstruction Treatment Market Regional And Country Analysis

• 7.1. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market

• 8.1. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intestinal Pseudo-Obstruction Treatment Market

• 9.1. China Intestinal Pseudo-Obstruction Treatment Market Overview
• 9.2. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intestinal Pseudo-Obstruction Treatment Market

• 10.1. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intestinal Pseudo-Obstruction Treatment Market

• 11.1. Japan Intestinal Pseudo-Obstruction Treatment Market Overview
• 11.2. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intestinal Pseudo-Obstruction Treatment Market

• 12.1. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intestinal Pseudo-Obstruction Treatment Market

• 13.1. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intestinal Pseudo-Obstruction Treatment Market

• 14.1. South Korea Intestinal Pseudo-Obstruction Treatment Market Overview
• 14.2. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intestinal Pseudo-Obstruction Treatment Market

• 15.1. Western Europe Intestinal Pseudo-Obstruction Treatment Market Overview
• 15.2. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intestinal Pseudo-Obstruction Treatment Market

• 16.1. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intestinal Pseudo-Obstruction Treatment Market

• 17.1. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intestinal Pseudo-Obstruction Treatment Market

• 18.1. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intestinal Pseudo-Obstruction Treatment Market

• 19.1. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intestinal Pseudo-Obstruction Treatment Market

• 20.1. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market

• 21.1. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market Overview
• 21.2. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intestinal Pseudo-Obstruction Treatment Market

• 22.1. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intestinal Pseudo-Obstruction Treatment Market

• 23.1. North America Intestinal Pseudo-Obstruction Treatment Market Overview
• 23.2. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intestinal Pseudo-Obstruction Treatment Market

• 24.1. USA Intestinal Pseudo-Obstruction Treatment Market Overview
• 24.2. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intestinal Pseudo-Obstruction Treatment Market

• 25.1. Canada Intestinal Pseudo-Obstruction Treatment Market Overview
• 25.2. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intestinal Pseudo-Obstruction Treatment Market

• 26.1. South America Intestinal Pseudo-Obstruction Treatment Market Overview
• 26.2. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intestinal Pseudo-Obstruction Treatment Market

• 27.1. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intestinal Pseudo-Obstruction Treatment Market

• 28.1. Middle East Intestinal Pseudo-Obstruction Treatment Market Overview
• 28.2. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intestinal Pseudo-Obstruction Treatment Market

• 29.1. Africa Intestinal Pseudo-Obstruction Treatment Market Overview
• 29.2. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Condtion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape And Company Profiles

• 30.1. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape
• 30.2. Intestinal Pseudo-Obstruction Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck Sharp & Dohme Corp Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Intestinal Pseudo-Obstruction Treatment Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Amgen PLC
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Astellas Pharma Inc.
• 31.7. Mylan N.V.
• 31.8. Biogen Inc.
• 31.9. Penn Medicine
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Aurobindo Pharma Ltd
• 31.12. Cipla Inc.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Allergan plc
• 31.15. Torrent Pharmaceuticals Limited

32. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intestinal Pseudo-Obstruction Treatment Market

34. Recent Developments In The Intestinal Pseudo-Obstruction Treatment Market

35. Intestinal Pseudo-Obstruction Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Intestinal Pseudo-Obstruction Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intestinal Pseudo-Obstruction Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intestinal Pseudo-Obstruction Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer